Docket No. MCP-242

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Harry S. Sowden

JUN 2 1 2004

Serial No.: 09/966,939 Art Unit: 1722

Filed : September 28, 2001 Examiner: Robert B. Davis

For : SYSTEMS, METHODS AND APPARATUSES FOR MANUFACTURING

DOSAGE FORMS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop DD, Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

> June 18, 2004 (Date of Deposit)

David R. Crichton (Name of applicant, assignee, or Registered Representative)

June 18, 2004

(Date of Signature)

Mail Stop DD Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

EIGHTH INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the aboveidentified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

01 FC:1806

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required. In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with | the first or \(\sigma\) second After Final Submission, therefore: П Statement in Accordance with §1.97(e) (attached); or Please charge Deposit Account No. 10-/ the fee of \$180.00 as set forth in §1.17(p).

In accordance with §1.97(c), this Information
Disclosure Statement is being filed after the period set forth
in §1.97(b) above but before the mailing date of either a Final
Action under §1.113 or a Notice of Allowance under §1.311, or
an action that otherwise closes prosecution and that it is
accompanied by one of:

Statement in Accordance with §1.97(e)
(attached); or
Please charge Deposit Account No. 10-
0750/MCP0242/DRC the fee of \$180.00 as set forth
in §1.17(p).
☐ In accordance with §1.97(d), this Information
Disclosure Statement is being filed after the mailing date of
either a Final Action under §1.113 or a Notice of Allowance
under §1.311 but before the payment of the Issue Fee.
Applicant(s) hereby petition(s) for consideration of this
Information Disclosure Statement. Included are: Statement in
Accordance with §1.97(e) as set forth below and the fee of
\$180.00 as set forth in §1.17(p).
☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.
Copies of references listed on the attached Form PTO-
1449 are enclosed herewith EXCEPT THAT:
In view of the voluminous nature of references
[list as appropriate], and the likelihood that
these references are available to the Examiner,
copies are not enclosed herewith.
If any of the foregoing publications are not
available to the Examiner, Applicant will
endeavor to supply copies at the Examiner's
request.
Copies of only foreign patent documents and non-
patent literature are enclosed in accordance with 37 CFR 1.98
(a) (2). (The U.S. patents and each U.S. patent application
publication listed on the attached Form PTO-1449 are not
pastication riscoa on the accuracy form the 1415 are not

enclosed because this U.S. patent application was filed after June 30, 2003 or this international application has entered the national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i).

There are no listed references which are not in the English language.
The relevance of those listed references which are not in the English language is as follows:

Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/MCP-242/DRC. This form is submitted in triplicate.

Respectfully submitted,

David R. Crichton Reg. No. 37,300

Attorney for Applicants

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-6131 DATED: June 18, 2004



PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to	o a collection of information unless it displays	a valid OMB control number.
form 1449A/PTO	Application Number	09/966,939
	Filing Date	September 28, 2001
DRMATION DISCLOSURE	First Named Inventor	Harry S. Sowden
TEMENT BY APPLICANT	Group Art Unit	1722
	Examiner Name	Robert B. Davis
(use as many sheets as necessary) Sheet 1 of 1	Attorney Docket Number	MCP 0242

				U.S. PATENT DOCUMENTS		
		U.S. Patent Document				
Examiner Initials	Cite No. ¹	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
				CAL DATEAU DOCUMENTO		

Examiner Cite Initials No.1	Foreign	Patent Docur	nent	Name of Patentee or Applicant of Cited Document	of Cited Document where relevant	Pages, Columns, Lines, where relevant	T ₆
	Office ³	Number⁴	KindCođe ⁵			passages or relevant figures appear	
				., -, -, -, -, -, -, -, -, -, -, -, -, -,			

Examiner's	Cite	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
THE COLUMN TO TH	110.	EITH, L., et al., "Injection-Moulded Drug-Delivery Systems", Manufacturing Chemist (January 1987), pp. 21-25.	

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.